

LB 1904 A COMPARISON OF CLINICAL OUTCOMES FROM ZUMA-5 (AXICABTAGENE CILOLEUCEL) AND THE INTERNATIONAL SCHOLAR-5 EXTERNAL CONTROL COHORT IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

Author(s): Paola Ghione Anik, Patel, Sabela Bobillo, Kevin Deighton, Caron Jacobson, Myrna Nahas, Anthony Hatswell, Steve Kanters, Julia Thornton Snider, Sattva Neelapu, Hervé Ghesquieres, Lia Palomba, John Radford, John Gribben

EHA Library. Gribben J. 06/12/21; 330174; LB1904

Presentation during EHA2021: The Late-Breaking Oral Session will be held on Saturday, June 12, 2021 (16:00 - 17:30 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: LB1904

Type: Oral Presentation

Session title: Late-Breaking Oral Session

Background

In the pivotal ZUMA-5 (Z-5) trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in r/r FL patients, including those with high-risk disease such as patients who progressed within 24 months of initiating first-line chemoimmunotherapy (POD24).

Aims

To compare clinical outcomes from updated 18-month Z-5 to a matched sample from the international SCHOLAR-5 (S-5) external control cohort.

Methods

The international S-5 cohort source data were extracted for r/r FL patients from 7 institutions in 5 countries who initiated a third or higher (3L+) line of therapy (LOT) after July 2014. Data from the pivotal idelalisib DELTA trial was also included in the S-5 cohort. Z-5 trial eligibility criteria were applied to the S-5 cohort, with patients excluded or censored upon transformation. The S-5 and Z-5 cohorts were balanced for patient characteristics through propensity scoring on prespecified prognostic factors and standardized mortality ratio weighting. Differences between treatment groups with a standardized mean difference (SMD) <0.1 were deemed balanced. Overall response rate (ORR) was compared using odds ratio (OR). Overall survival (OS), progression-free survival (PFS) and time to next treatment (TTNT) were evaluated using Kaplan-Meier analysis and hazard ratios (HR).


Results

143 patients were identified in S-5, reducing to 85 patients after applying propensity score weights along with 86 patients in Z-5. Median follow-up time for Z-5 was 23.3 months and for S-5 was 26.2 months. Variables that were successfully matched (SMD<0.1) included POD24, number of prior LOT, relapsed vs refractory, prior stem cell transplant, size of largest node, response to prior LOT, time since last therapy and age. Despite matching, the S-5 cohort had a higher proportion of ECOG 1 vs 0 (71.0% vs 40.7%) at baseline.

In 3L+ patients, the ORR was 42/85 (49.9%) in S-5 compared to 81/86 (94.2%) for an OR of 16.2 (95% confidence interval [CI]: 5.6-46.9). The median PFS and OS were not reached in Z-5 and in S-5 were 12.7 months and 59.8 months, respectively (Table 1). The HRs for OS and PFS were 0.42 (95%CI: 0.21-0.83) and 0.30 (95%CI: 0.18-0.49; Figure 1). In sub-group analysis of 4L+ patients, improvements in all time-to-event outcomes were more pronounced (Table 1).

Table 1. Matched time-to-event outcomes

		18 months %(95% CI)		Median month (95% CI)		Hazard ratio (95% CI)	p-value
		SCHOLAR-5	ZUMA-5	SCHOLAR-5	ZUMA-5		
Primary analysis: 3L+	OS	67.1 (54.1, 80.2)	88.3 (79.4, 93.5)	59.8 (21.9, -)	NR (31.6, -)	0.42 (0.21, 0.83)	0.013
	PFS	23.8 (11.0, 36.5)	68.8% (57.4, 77.8)	12.7 (6.2, 14.7)	NR (23.5, -)	0.30 (0.18, 0.49)	<0.001
	TTNT	47.2 (34.2, 60.2)	69.7 (58.8, 78.3)	14.4 (6.2, 25.8)	NR (-, -)	0.42 (0.26, 0.68)	<0.001
Sub-group analysis: 4L+	OS	55.0 (39.6, 70.3)	88.3 (77, 94.2)	28.4 (12.3, -)	NR (31.6, -)	0.31 (0.15, 0.66)	0.003
	PFS	12.7 (0.7, 24.6)	67.0 (52.7, 77.8)	3.5 (1.8, 12.9)	NR (19.0, -)	0.20 (0.11 to 0.34)	<0.001
	TTNT	37.7 (22.0, 53.4)	68.3 (54.9, 78.5)	6.9 (5.1, 23.5)	NR (22.8, -)	0.38 (0.21, 0.68)	0.001



Conclusion

Compared to currently available therapies in r/r FL patients, axi-cel demonstrated a substantial and statistically significant improvement in meaningful clinical endpoints including ORR, PFS, TTNT and OS, highlighting the durable treatment effect of axi-cel. These findings suggest that axi-cel addresses an important unmet medical need for r/r FL patients.

Keyword(s): CAR-T, Clinical data, Indolent non-Hodgkin's lymphoma